Table 2:
Examples of cells encapsulated AMS (arranged according for formulation method)
Therapeutic agent | Formulation method | Materials used | Findings | Reference |
---|---|---|---|---|
Dental pulp stem cells (DPSC) | Emulsification | Calcium-AMS | Enhanced osteogenic potential of cells, maintained high cell viability for bone tissue regeneration | (Kanafi et al., 2014) |
Enterococcus faecalis | Emulsification | Milk, alginate | Good tolerance to stimulated gastric fluid and bile salt solution (1.0 or 2.0%), improved storage stability of E. faecalis | (Shi et al., 2016) |
Allogeneic pancreatic islet cells | Emulsification | Chemically modified alginate derivative Z1-Y15 | Three of the several chemically modified AMS elicited a reduced foreign body response, are now in clinical trials. | (Bochenek et al., 2018) |
Mesenchyma l stem cells (MSC) | Microfluidics with calcium crosslinking | Sodium alginate, calcium chloride-ethylenediam ine tetra acetic acid. | MSC encapsulated within homogenous AMS, stable cell growth and proliferation for 15 days. | (Utech et al., 2015) |
Modified human pancreatic islets cells (1.1B4) | Microfluidics | Alginatepoly-L-lysine-copolymer | Microspheres formulated as microcapsules in the static state and using microfluidics in dynamic state. Cell viability and glucose simulated insulin secretion better in microcapsules formulated by dynamic microfluidics method | (Acarregui et al., 2018) |
MSC | Co-axial air-flow droplet generator | Alginate-polyethylene glycol microspheres | Encapsulated MSC displayed anti-fibrotic and anti-inflammatory effects on liver fibrosis in mice due to secretion of soluble factors | (Meier et al., 2015) |